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ARTICLE
DLX5 and DLX6 Expression Is Biallelic and Not Modulated
by MeCP2 Deﬁciency
Birgitt Schu¨le, Hong Hua Li, Claudia Fisch-Kohl, Carolin Purmann, and Uta Francke
Mutations in MECP2 and Mecp2 (encoding methyl-CpG binding protein 2 [MeCP2]) cause distinct neurological phe-
notypes in humans and mice, respectively, but the molecular pathology is unclear. Recent literature claimed that the
developmental homeobox gene DLX5 is imprinted and that its imprinting status is modulated by MeCP2, leading to
biallelic expression in Rett syndrome and twofold overexpression of Dlx5 and Dlx6 in Mecp2-null mice. The conclusion
that DLX5 is a direct target of MeCP2 has implications for research on the molecular bases of Rett syndrome, autism,
and genomic imprinting. Attempting to replicate the reported data, we evaluated allele-speciﬁc expression of DLX5 and
DLX6 in mouse# human somatic cell hybrids, lymphoblastoid cell lines, and frontal cortex from controls and individuals
with MECP2 mutations. We identiﬁed novel single-nucleotide polymorphisms in DLX5 and DLX6, enabling the ﬁrst
imprinting studies of DLX6. We found that DLX5 and DLX6 are biallelically expressed in somatic cell hybrids and in
human cell lines and brain, with no differences between affected and control samples. We also determined expression
levels of Dlx5 and Dlx6 in forebrain from seven male Mecp2-mutant mice and eight wild-type littermates by real-time
quantitative reverse-transcriptase polymerase chain reaction assays. Expression of Dlx5 and Dlx6, as well as of the im-
printed gene Peg3, in mouse forebrain was highly variable, with no consistent differences between Mecp2-null mutants
and controls. We conclude that DLX5 and DLX6 are not imprinted in humans and are not likely to be direct targets of
MeCP2 modulation. In contrast, the imprinting status of PEG3 and PEG10 is maintained in MeCP2-deﬁcient tissues. Our
results conﬁrm that MeCP2 plays no role in the maintenance of genomic imprinting and add PEG3 and PEG10 to the
list of studied imprinted genes.
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Rett syndrome (RTT [MIM #312750]) is a neurodevelop-
mental disorder that affects females almost exclusively. An
apparently normal early-postnatal period is followed by
developmental stagnation and then regression, with loss
of motor skills and speech, autonomic dysfunction, and
seizures.1 De novo recurrent loss-of-functionmutations of
the X-linked gene MECP2 (MIM 300005) are found in
almost all girls who receive a clinical diagnosis of RTT2
(for review, see the work of Francke3). The incidence is
estimated to be 1 in 10,000 female births, and the avail-
ability of molecular diagnostic testing leads to earlier di-
agnosis, before the clinical picture is fully developed.
MECP2 encodes methyl-CpG binding protein 2 (MeCP2),
a multifunctional protein that is expressed ubiquitously
but at the highest levels in neurons. SinceMECP2 is subject
to X inactivation, affected females are mosaic for cells that
either have normal MeCP2 levels or lack MeCP2 function
completely. Classic RTT is associated with random X-in-
activation patterns, but skewed X-chromosome inacti-
vation leads to phenotypic variants.4,5 Most males with
inactivating MECP2 mutations have congenital enceph-
alopathy, with lack of postnatal development, and respi-
ratory insufﬁciency that usually leads to early death.6 Re-
cent elegant experiments with genetically manipulated
mouse models revealed that the symptoms can be pre-
vented or delayed7 and even reversed8 when normal
MeCP2 function is restored postnatally.
One of the functions of MeCP2 is to repress transcrip-
tion of methylated genes by recruiting a chromatin re-
modeling complex to promoter regions.9 Therefore, lack
of MeCP2 is expected to cause abnormal expression of
genes that affect postnatal neuronal function. Although
large-scale misregulation of gene expression has not been
observed, a few target genes have been identiﬁed by global
gene-expression studies.10–17 Imprinted genes that are tran-
scribed exclusively from thematernal or the paternal allele
are attractive candidates for potential MeCP2modulation,
because their uniparental expression pattern is controlled
by parent-of-origin–speciﬁc methylation of speciﬁc sites
(differentially methylated regions [DMRs]).18 Of the ∼80
known imprinted genes in mammals,19 5 (SNRPN, IPW,
NDN, H19, and IGF2) were previously studied in RTT tis-
sues. These genes showed monoallelic expression in
MeCP2-deﬁcient clonal cell lines and brain.20 Although
Samaco et al.21 and Makedonski et al.22 reported decreased
expression levels of the brain-imprinted genes UBE3A and
Ube3a in MeCP2-deﬁcient human and mouse brain tis-
sues, respectively, these data could not be replicated in a
more extensive study of Ube3a RNA and protein expres-
sion in Mecp2-mutant mouse brains.23
Hailed as a breakthrough discovery with a major impact
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on RTT research was the work by Horike et al.24 that re-
ported that MeCP2 regulates the expression of the distal-
less homeobox 5 gene (DLX5). Under the assumption that
DLX5 is imprinted, the authors claimed loss of imprinting
in MeCP2-deﬁcient cell lines and brain. In an Mecp2-mu-
tant mouse model,25 expression levels of Dlx5 and Dlx6
were reported to be increased twofold in the frontal cortex.
This increase was said to be the result of “relaxed imprint-
ing,” although Dlx5 is known to be biallelically expressed
in mice.26 Horike et al.24 concluded that DLX5 is a direct
target of MeCP2 modulation, and this conclusion is now
widely quoted in the literature.
Using a wide range of methodologies, Horike et al.24
reported a series of observations that are not coherent.
First, searching for in vivo binding sites of MeCP2, they
precipitated urea-gradient–puriﬁed, formaldehyde–cross-
linked chromatin, derived from whole brains of 1-d-old
normal mice, with anti-MeCP2 antibody and cloned the
precipitated DNA fragments. Of 100 randomly sequenced
clones, only 3 contained CpG dinucleotides andwere con-
sistent with promoters. The others were located in introns
or up to 100 kb away from the ends of the nearest tran-
scription unit. Scanning the vicinity of apparent MeCP2-
binding sequences for biologically interesting candidates,
Horike et al.24 focused on DLX5 for two reasons. First,
DLX5 directly regulates expression of glutamic acid de-
hydroxylase and promotes differentiation of GABAergic
neurons,27 and, second, DLX5 had previously been re-
ported to be imprinted in human lymphoblasts and brain
tissues,28 although not in mouse brain.26
DLX genes encode a family of transcription factors that
contain a homeobox DNA-binding domain related to that
of the Drosophila gene distal-less.29 In mammalian ge-
nomes, the six known DLX genes occur in pairs that are
closely linked. DLX5 and DLX6 are located within a 20-
kb region in a tail-to-tail conﬁguration on human chro-
mosome 7q21.3 and mouse chromosome 6A1. During de-
velopment, DLX5 and DLX6 are expressed in deﬁned
regions of the brain and in skeletal structures. DLX5 in-
duces bone formation and is expressed in later stages of
osteoblast differentiation. Dlx5-knockout mice have mul-
tiple defects in their ears, noses, mandibles, and skull
bones and die shortly after birth.30 A proportion of them
have exencephaly.31 Early developmental defects in neu-
rogenesis have also been recognized.32 Notably, develop-
mental defects were seen only in homozygous mutants,
not in heterozygotes with a parent-of-origin–dependent
effect, as would be expected if Dlx5 were an imprinted
gene.
Evidence that DLX5 is imprinted in humans was ﬁrst
reported by Okita et al.,28 who studied somatic cell hybrid
(SCH) lines containing a single human chromosome 7 of
deﬁned parental origin. DLX5 was not expressed in SCHs
containing a paternal chromosome 7 but was expressed
in cells containing a maternally derived chromosome 7.
The hybrid cell studies of 76 ESTs from the 7q21-q31 re-
gion revealed monoallelic expression for six transcripts,
but DLX5 was the only one for which imprinting status
could be conﬁrmed by studies of human lymphoblastoid
cell lines (LCLs) and brain. Speciﬁcally, Okita et al.28 stud-
ied LCLs from 15 individuals who were heterozygous
for an intragenic polymorphism in DLX5 (c.*163dupC
[rs5886002]; the alleles are referred to as “-/G” in dbSNP).
RT-PCR products were sequenced and were said to reveal
monoallelic expression in 13 of the 15 samples. In all eight
cases in which the parental origin of the alleles could be
determined, DLX5 was reported to be expressed only from
the maternal allele. The authors also examined the allelic
expression of DLX5 in brain tissue samples from three
c.*163dupC heterozygotes. Sequence analysis of RT-PCR
products revealed biallelic but unequal expression, pref-
erentially from a single allele of unknown parental origin.
Nevertheless, Okita et al. concluded that “DLX5 is im-
printed and maternally expressed in normal human lym-
phoblasts and brain tissues.”28(p557)
Horike et al.24 used the same c.*163dupCpolymorphism
to assess the imprinting status of DLX5 in LCLs from in-
dividuals with RTT and controls. By using RT-PCR with
40 cycles, they reported monoallelic expression in two
normal control LCLs and in only one of four RTT LCLs.
They interpreted these results to indicate “loss of imprint-
ing” in RTT.
In the mouse, Kimura et al.26 reported that Dlx5 is not
imprinted. They studied offspring of interspecies crosses,
distinguished by a SNP in the 3′ UTR of Dlx5, as well as
heterozygous Dlx5-knockout mice that had inherited the
knockout allele from either parent. Both approaches re-
vealed that Dlx5 is expressed in a biallelic fashion in ce-
rebral cortex, diencephalon, olfactory bulb, hippocampus,
and testis, with no allele-speciﬁc preference. Furthermore,
the CpG islands of the Dlx5 and Dlx6 promoters were
unmethylated on both alleles in wild-type and Mecp2 Y/-
mice.24 Moreover, no differential methylation was de-
tected at other CpG sites in the Dlx5/Dlx6 region between
the two alleles, either in wild-type or in Mecp2-mutant
mice. The absence of DMRs is consistent with the observed
lack of imprinting of Dlx5 and Dlx6 in mouse brain.
Horike et al.24 assessed expression of Dlx5 and Dlx6 in
mouse brain, ﬁrst by quantitative RT-PCR (qRT-PCR) ex-
periments on brain samples from an unspeciﬁed number
of 8-wk-old wild-type and Mecp2-mutant mice. When rel-
ative expression levels for Dlx5 and Dlx6, as well as for
other imprinted and nonimprinted genes, were compared,
only Dlx5 and Dlx6 showed an approximately twofold
increase in themutant samples comparedwith in thewild-
type samples. To determine whether the increased ex-
pression was allele speciﬁc, Horike et al. examined the SNP
in the 3′ UTR of Dlx5 in interspecies crosses, as was done
previously by Kimura et al.26 On the basis of the intensity
of restriction-enzyme fragments of RT-PCR products, Hor-
ike et al. conﬁrmed that Dlx5 was biallelically transcribed
in frontal cortex, but transcript levels were said to be
higher for the maternal allele. However, in an Mecp2-mu-
tant male mouse, which was heterozygous for the Dlx5
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SNP, both parental-speciﬁc restriction fragments were pre-
sent at equal levels, which led the authors to conclude
that MeCP2 deﬁciency abolished the albeit incomplete
imprinting pattern. Notably, the transcript levels and pa-
rental-speciﬁc expressions of four other, truly imprinted
genes (Calcr, Sgce, Peg10, and Asb4), located in the same
gene cluster on chromosome 6, were not affected by
MeCP2 deﬁciency.
To examine the validity of the fundamental claims that
led to the identiﬁcation of DLX5 as a primary target of
MeCP2, we attempted to reproduce the reported data in
a systematic fashion. First, in two sets of SCHs with single
paternal or maternal copies of chromosome 7, we found
expression of both alleles of human DLX5 and DLX6. Sec-
ond, both genes were consistently expressed in a biallelic
fashion in LCLs and brain samples from normal individ-
uals and in clonal RTT LCLs. To evaluate whether MeCP2
deﬁciency relaxes the imprinting of truly imprinted genes
in humans, we studied allele-speciﬁc expression of Pater-
nally expressed gene 3 (PEG3) on chromosome 19 and
Paternally expressed gene 10 (PEG10) near the DLX5 and
DLX6 genes on 7q. We demonstrated strictly monoallelic
expression of PEG3 and PEG10 in tissues from males and
females with MECP2 mutations. Third, to evaluate the al-
ternative hypothesis—also put forward by Horike et al.,24
that differential chromatin loop formation affecting the
expression of both alleles, rather than allele-speciﬁc im-
printing, could control Dlx5 transcript levels in different
brain regions—we compared expression levels ofDlx5 and
Dlx6 in the forebrain ofMecp2-mutant malemice and nor-
mal male littermates. We saw no differences when we
combined data from seven different litters of mice aged
7–9 wk. Our results provide strong evidence against the
claim that DLX5 and DLX6 are targets of MeCP2 and play
a role in the pathogenesis of RTT.
Material and Methods
SCHs
Human blood leukocytes from unaffected donors were fusedwith
the Hprt-deleted mouse cell line A9. SCHs were selected in hy-
poxanthine-aminopterin-thymidine medium, which forces re-
tention of the human X chromosome. Hybrid cell clones were
genotyped for eight microsatellite markers on human chromo-
some 7, to identify those that had retained a single copy of chro-
mosome 733 (performed by GMP Genetics). Genotyping of the
donors’ parents for the loci with distinguishing alleles allowed
us to assign maternal or paternal origin of the chromosome 7
that was present. Chromosome 7 retention was not selected for
in the hybrid clones, andwe did not determine the copynumbers.
Hybrid cell lines were grown in Dulbecco’s modiﬁed Eagle me-
dium with 10% fetal calf serum, 2 mM glutamine, and 1# hy-
poxanthine and thymidine and were subcultured at 1:3 with
TrypLE (GIBCO), by use of standard tissue-culture techniques.
LCLs and Brain Samples
For detection and genotyping of DLX5 and DLX6 polymor-
phisms, we sequenced 14 LCLs previously established in our lab-
oratory from RTT-affected individuals with known MECP2 mu-
tations, 22 unaffected control LCLs, and six fetal and six adult
control brain samples. ForDLX5, 15 additional control brain sam-
ples were genotyped. For two PEG3 SNPs, we genotyped the RTT
LCLs and seven brain samples from individuals with RTT, in-
cluding two hemizygous males with known MECP2 mutations
(University ofMaryland Brain and Tissue Bank forDevelopmental
Disorders [numbers 1238, 1420, 1748, 1815, 4516, and 4852]).
One sample from the Harvard tissue bank is brain sample number
b4160. Only the brain samples were genotyped for PEG10 SNPs.
Frozen tissue used for the expression studies was from frontal
cortex. All human materials were obtained and studied under a
protocol approved by the Stanford Human Research Protection
Program.
DNA Extraction and Genotyping
We extracted DNA from cultured cells, by using phenol-chloro-
form, and from brain tissue, by using DNA Stat 60 (Tel-Test). For
PCR, we used Promega Go Taq in accordance with the manufac-
turer’s instructions, with the primers listed in table 1, in a 25-ml
reaction. The PCR cycling program included an initial denatur-
ation at 95C for 4 min, followed by ﬁve cycles at 94C for 30 s,
annealing at 60C for 30 s, and extension at 72C for 30 s. The
annealing temperature was reduced by 0.5C in the second to
ﬁfth cycle. For 30 additional cycles, the annealing temperature
was 54C for the DLX5 genomic DNA (gDNA) primers and was
57C for the DLX5 cDNA primers, as well as for the DLX6, PEG3,
and PEG10 primers. The gel-puriﬁed PCR amplicons were se-
quenced using BigDye Terminator chemistry on an ABI 3100 se-
quencer (Applied Biosystems). For conﬁrmatory studies of the
DLX5 c.*163dupC polymorphism, we used a proofreading DNA
polymerase (Platinum Pfx [Invitrogen]) to minimize slippage er-
rors during the ampliﬁcation of the mononucleotide strings.
RNA Extraction, cDNA Synthesis, and RT-PCR Assay
We extracted total RNA from mouse # human SCH lines and
frozen human cortex, using RNA Stat 60 (Tel-Test). From the LCLs,
we extracted mRNA by use of Oligotex Direct mRNA Mini Kit
(Qiagen). We treated the RNA with 20 U RNase-free DNaseI
(Roche) for 20 min, followed by 10 min of inactivation of the
enzyme at 75C. For reverse transcription, 5 mg total RNA or 1 mg
mRNA was incubated with Superscript III (Invitrogen), as rec-
ommend by the manufacturer, in a 40-ml reaction. For each re-
action, we used a “minus RT” control, to which no Superscript
III was added. For DLX5, DLX6, PEG3, and PEG10 RT-PCR assays,
we used gene-speciﬁc primers (table 1) and 4 ml of the cDNA
reaction with Promega Go Taq Flexi, in accordance with theman-
ufacturer’s instructions. PCR cycling and sequencing of ampli-
cons were done as described above.
Mecp2-Mutant Mice
Female mice heterozygous for the Mecp2tm1.1Bird mutation25 were
purchased from the Jackson Laboratory and were bred with
C57BL/6Jmalemice. Tail DNA samples were genotyped forMecp2,
as described elsewhere.23 Mutant male mice and wild-type male
littermates at age 7–9 wk were euthanized with CO2. Forebrains
(the frontal one-third of the cortex) were dissected and were snap
frozen on dry ice. The Animal Care Committee of Stanford Uni-
versity approved all experimental procedures.
Table 1. Primers for Genotyping and Expression Analysis













DLX5 c.*163dupC (rs5886002) -/G TTTTTTGGGACTACTGTGTTTTGC AGATTTCAAGGCACCATTGAAAG 203 GCTGGGATTGACACAAACAC AGGCACCATTGAAAGTGTCC 568
DLX5 c.*142TrC T/C Same as above Same as above Same as above Same as above
DLX5 5′ UTR … … … … GCCACAACAGCAAGGACAG TTTGCCATTCACCATTCTCA 440
DLX6 c.*9ArG (rs3213654) A/G CTCCAGTCTGGGACGTTTCT GCTCTCCTAAGCCTGCTCCT 232 TCGCTTTCAGCAGACACAGT CGGCTTCTTGCCACACTTAT 457
DLX6 c.*775dupC -/C AAGGGAATGCTGCATGTTTT TAGCTTTGTGAATGCCACCA 202 Same as for gDNA Same as for gDNA …
DLX6 c.*771CrT (rs2272280) C/T Same as above Same as above Same as above Same as above
PEG3 c.*703ArG (rs1055359) A/G CTTGTGAAGCTGTAGGCATGA CTGGGTCACAAAAAGCCAAT 163 Same as for gDNA Same as for gDNA …
PEG3 c.42CrT (rs1860565) C/T GGGATGGGTACTCACCACTG CAGGTCATTCCAACCATGTG 218 AAGCCGGAGAACTGTGAGAA CTTCTTGGGTTCCTGGTGTG 239
PEG10 c.*2923TrC (rs13073) C/T GTGTCATTTTCCTGCCTGGT AGGAGCCTCTCATTCACAGC 410 Same as for gDNA Same as for gDNA
Mouse:
Dlx5 … … … … TCTCTAGGACTGACGCAAACA GTTACACGCCATAGGGTCGC 132
Dlx6 … … … … TTCCCGAGAGAGCCGAACT GTGGGTTACTACCCTGCTTCA 117
Peg3A … … … … CACGAAGACGACACCAACAG GTCTCGAGGCTCCACATCTC 150
Peg3B … … … … ACAGTGACGACGACATGAGC GTCTCGAGGCTCCACATCTC 122
Rps28 … … … … TAGGGTAACCAAAGTGCTGGGCAG GACATTTCGGATGATAGAGCGG 103
b-actin … … … … TGACCCTGAAGTACCCCATTGA CCATGTCGTCCCAGTTGGTAAC 54
Snca … … … … GCAGCCAGAAGTCGGAAA TGAACACATCCATGGCTAAAGA 58
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Figure 1. Absence of imprinting of DLX5 and DLX6 in SCH lines.
RT-PCR analysis of human DLX5 and DLX6 expression in mouse #
human SCHs containing a single copy of human chromosome 7
shows that both genes are expressed from the maternally (M) as
well as the paternally (P) derived chromosome 7. One SCH line in
set 1 had apparently lost the maternal chromosome 7, and one
line in set 2 had retained the maternal chromosome 7 at a low
copy number. Primers used do not amplify the mouse (Mus) or-
thologues in C57BL/6 cortex. Mouse Snca expression is shown as
a loading control. NTC p no template control; -RTp ﬁrst-strand
synthesis without reverse transcriptase.
Real-Time qRT-PCR of Dlx5, Dlx6, and Peg3 in Mouse
Brain
We extracted total RNA from frozen brain tissues by using TRIzol
reagent (Invitrogen). We treated 2 mg of total RNAwith 2 UDNase
I (Ambion) and reverse transcribed it with random hexamers and
Superscript II (Invitrogen). After real-time qRT-PCR with Sybr
Green on an ABI 5700 instrument (AME Bioscience), we analyzed
melting curves for each reaction, to ensure a single peak. Actb
and Rps28 served as RNA controls for relative quantitation (User
Bulletin 2 [Applied Biosystems]). Details of the methods were as
described in previous articles from our laboratory.12,34 Primer se-
quences are listed in table 1. Dlx5 primers (nt 617–636 and nt
748–729 of GenBank accession number NM_198854.1) span the
last two exons—that is, exons 2 and 3 or exons 3 and 4, depending
on the transcript variant. Dlx6 primers (nt 339–319 and nt 223–
241 of GenBank accession number BC114342.1) span exons 2
and 3. For Peg3, two different primer sets were used: Peg3A, span-
ning exons 2, 3, and 4, and Peg3B, spanning exons 3 and 4.
Results
Expression of Human DLX5 and DLX6 from Maternal and
Paternal Chromosome 7 in Mouse # Human SCH Lines
We examined eight SCH lines, four each derived from two
unrelated individuals. In both sets, two lines had retained
the maternal copy of chromosome 7 and two had retained
the paternal copy, as determined by STR genotyping.
DLX5 and DLX6 were consistently expressed from both
alleles in seven of the eight SCH clones (ﬁg. 1). Quanti-
tative expression differences between clones are likely
caused by different retention frequencies of chromosome
7 in the SCH lines, and the one exceptional clone with
no transcript had apparently lost chromosome 7 during
propagation of the culture. For a loading control, we stud-
ied mouse Snca expression. The DLX5 primers speciﬁcally
amplify the human transcript, including the 5′ UTR, exon
1, and part of exon 2. The forward primer is complemen-
tary only to human DLX5, and the reverse primer has
sevenmismatches with themouseDlx5 sequence. The two
DLX6 primers from the 3′ UTR had four and two mis-
matches with the Dlx6 sequence. Both sets of primers did
not amplify mouse cDNA, since no transcripts were ob-
tained from the SCH without chromosome 7 or from
mouse control brain. When we sequenced DLX5 and
DLX6 RT-PCR products from SCH lines, both were 100%
identical to the human cDNA sequences. Thus, our results
provide clear evidence of biallelic expression of DLX5 and
DLX6 from both parent-speciﬁc copies of human chro-
mosome 7 retained in mouse # human SCHs. Our data
contradict a previous report of maternal-speciﬁc im-
printed expression of DLX5.28 The imprinting status of
DLX6 had not been determined previously.
Biallelic Expression of DLX5 in RTT LCLs, Normal LCLs,
and Normal Human Brain
Next, we tested expression and imprinting status of
DLX5 in LCLs and brain samples by studying the same
c.*163dupC polymorphism that previously was used to
distinguish the two alleles24,28 (ﬁg. 2A). To identify het-
erozygotes, we sequenced gDNA from 36 human LCLs and
27 brain samples. We conﬁrmed the results with a second
round of sequencing, using a proofreading polymerase.
Three LCLs initially designated as heterozygous were
found to be C7 homozygotes after resequencing. Fre-
quencies of c.*163dupC heterozygotes were 5/14 for RTT
LCLs, 6/22 for normal LCLs, and 6/27 for normal brains.
A novel SNP, c.*142TrC, was discovered in one sample
(ﬁg. 2B). Allele frequencies are provided in table 2.
By RT-PCR analysis, DLX5 was biallelically expressed in
all 13 heterozygous samples that showed expression levels
sufﬁciently high for analysis (ﬁgs. 2 and 3). The results are
unlikely to be caused by gDNA contamination, because
the primers used for ampliﬁcation spanned an intron, and
no PCR product was obtained in the absence of reverse
transcriptase in the ﬁrst-strand cDNA synthesis reaction.
The sequence tracings suggest apparently equal ampliﬁ-
cation of transcripts from both alleles in most LCLs from
individuals with RTT and unaffected controls, except for
the sample with p.R106W and control 1, for which the
cDNA results suggest preferential ampliﬁcation of the C7
allele. Similar skewing is apparent, however, for the gDNA
samples with p.T158M and p.R106W and likely is caused
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Figure 2. Absence of imprinting of DLX5 in LCLs. A, Biallelic expression revealed by DLX5 genotyping (of gDNA) and expression analysis
(of cDNA) of LCLs from three females with RTT and common MECP2 mutations, as indicated, and three normal controls. All six LCLs are
heterozygous for the DLX5 c.*163dupC polymorphism (rs5886002) (left panel), and all show that both alleles are expressed (right panel).
The sequence shown is the sense strand. Arrows indicate the positions of nucleotide changes. B, Novel DLX5 SNP c.*142TrC detected
in a normal LCL, denoted by an arrow in the gDNA. Comparison with the reference sequence (Ref. seq. [GenBank accession number
NM_005221.5) shows that the SNP is located upstream of rs5886002. LCLs from control 4 are heterozygous for both SNPs, and both
alleles are expressed in cDNA.
by PCR artifacts during ampliﬁcation of the C7/C8 alleles
(ﬁg. 2). There was no obvious difference between the het-
erozygous clonal RTT LCLs that expressed either mutant
MECP2 in 100% of cells (p.R168X and p.T158M) or wild-
type MECP2 in 100% of cells (p.R106W).12
The low expression levels of DLX5 and DLX6 in LCLs
presented a considerable challenge. Initially, when we
raised the PCR cycle number to 40, we occasionally saw
expression of only one or the other allele, but not in a
parent-of-origin–speciﬁc manner. These results were not
reproducible and were probably caused by the very low
copy number of transcripts. We obtained consistent and
reproducible biallelic expression only when we performed
RNA extraction, ﬁrst-strand cDNA synthesis, and PCR am-
pliﬁcation in one session, avoiding freeze-thaw cycles of
the samples. In contrast, RT-PCR of all six frontal cortex
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DLX5 c.*163dupC rs5886002 64 - p .87 C p .13
DLX5 c.*142TrC No record 50 T p .99 C p .1
DLX6 c.*9ArG rs3213654 46 A p .98 G p .2
DLX6 c.*775dupC No record 50 - p .99 C p .1
DLX6 c.*771CrT rs2272280 50 C p .98 T p .2
NOTE.—Reference sequences were DLX5 (GenBank accession number
NM_005221.5) and DLX6 (GenBank accession number NM_005222.2). All
variants are described in accordance with guidelines from den Dunnen
and Antonarakis35; updates can be found at HGVS Nomenclature for the
Description of Sequence Variants.
samples from non-RTT donors generated strong and un-
ambiguous biallelic expression of DLX5 (ﬁg. 3). We con-
clude that DLX5 is not imprinted in human LCLs and
cortex.
Biallelic Expression of DLX6 in Normal Human Brain
The imprinting status of DLX6 had not been determined
previously because of a lack of suitable polymorphisms.24
We screened our LCLs and brain samples for hetero-
zygosity at two rare SNPs (c.*9ArG [rs3213654] and
c.*771CrT [rs2272280]) that are located ∼800 nt apart in
the 3′ UTR and are in linkage disequilibrium. One of 22
normal LCLs and 1 of 12 non-RTT brain samples were
heterozygous for both SNPs. In addition, one fetal brain
gDNA showed a novel c.*775dupC variant. By RT-PCR,
DLX6 expression in the LCLs was too low for reproducible
results; however, we obtained reliable data for the two
brain samples, and both showed biallelic expression of
DLX6 (ﬁg. 4).
Monoallelic Expression of Imprinted Genes PEG3 and
PEG10 in MeCP2-Deﬁcient Tissues
Because we were unable to conﬁrm that DLX5 and DLX6
are imprinted in humans, our results could not address
the question of whether MeCP2 deﬁciency leads to “re-
laxation of imprinting” in our samples. Therefore, we ini-
tially examined the bona ﬁde imprinted gene PEG3 as a
positive control. Of 13 RTT LCLs, 7 were heterozygous for
the common c.42CrT polymorphism (rs1860565). We
tested the allele-speciﬁc PEG3 expression of three LCLs
carrying different MECP2 mutations (p.R106W, p.R168X,
and c.806delG). By using the androgen-receptor assay and
MECP2 expression analyses, we had previously discovered
completely skewed X-inactivation patterns in these three
LCLs.12 Although the p.R168X LCLs expressed the mutant
MECP2 allele in 100% of cells, the p.R106Wand c.806delG
LCLs were 100%wild type forMECP2 expression. All three
LCLs showed strictly monoallelic expression of PEG3 (ﬁg.
5A), indicating that imprinting of this gene is maintained
in the absence of MeCP2 protein.
To assess the PEG3 imprinting status in brain, we tested
ﬁve brain samples from females with RTT for two PEG3
SNPs, c.*703ArG (rs1055359) and c.42CrT (rs1860565),
and identiﬁed three heterozygotes. One had no known
MECP2 mutation, the second had missense mutation
c.451GrT (p.D151Y), and the third was reported to have
c.378-2ArG, affecting the 5′ splice site of exon 4. By RT-
PCR analysis of this brain sample, we were able to docu-
ment that this mutation leads to abnormal splicing, caus-
ing a frameshift and premature stop codon. The mutant
and wild-type MECP2 transcripts were ampliﬁed to similar
degrees (data not shown).We also included two brain sam-
ples from males with congenital encephalopathy who
were hemizygous for c.806delG and c.1154_1185del32
MECP2 mutations and heterozygous for one of the PEG3
SNPs. All ﬁve brain samples showed strictly monoallelic
expression of PEG3 (ﬁg. 5A).
To extend the control studies to another imprinted
gene, we selected PEG10 because it is located on chro-
mosome 7 near the DLX5 and DLX6 loci. Three of our six
MECP2-mutant brain samples genotyped for SNPs, one
male and two female, were heterozygous for the common
PEG10 SNP c.*2923TrC (rs13073). Only one PEG10 allele
was expressed in each of the samples (ﬁg. 5B). We con-
clude that the MeCP2 protein is not necessary for the
maintenance of PEG3 and PEG10 imprinting in human
brain.
Highly Variable Expression Levels of Dlx5, Dlx6, and Peg3
in Mouse Brain
Although Dlx5 is not imprinted in mouse, Horike et al.24
reported a twofold increase in expression ofDlx5 andDlx6
in Mecp2-mutant brain compared with that in control
brain. To explain that increase, they postulated that
MeCP2 induces a speciﬁc “silent chromatin loop” for-
mation that affects expression levels, presumably on both
alleles. As the ﬁrst step to evaluate the validity of this
model, we attempted to reproduce the reported expression
changes.
We established robust qRT-PCR assays on mouse fore-
brain in which Dlx5 and Dlx6 are highly expressed. Both
the Dlx5 and Dlx6 primers span an intron, and the Dlx5
primers amplify both splice variants. We used mice with
the same mutant allele (Mecp2tm1.1Bird) on the same strain
background (C57BL/6J) and bred them with mice of the
same age (7–9 wk) as in the previously published report.
We normalized qRT-PCR data for Dlx5 and Dlx6 to two
housekeeping genes whose expression is not affected by
MeCP2 deﬁciency at that age: Actb (encoding b-actin) and
Rps28.17 We then compared the relative transcript levels
of Dlx5 and Dlx6 in 15 male mice (7 Mecp2-mutant and
8 wild-type mice) from seven different litters. When all
data were combined, P values were not signiﬁcant (ﬁg.
6A). We show the actual data, to allow comparisons
among littermates. The range of variation (“biological
noise”) is quite striking. Although selective presentation
of a subset of these data could yield statistically signiﬁcant
results, by studying a larger number of animals, we were
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Figure 3. Absence of imprinting of DLX5 in frontal cortex. DLX5 genotyping (of gDNA) and expression analysis (of cDNA) of frontal
cortex brain samples from unaffected controls revealed biallelic expression. All six donors (age and sex indicated) were heterozygous
for the c.*163dupC (rs5886002) polymorphism (left panel). In all brain samples, both alleles are expressed at a similar level (right
panel). Arrows indicate the positions of nucleotide changes.
unable to conﬁrm that expression of Dlx5 and Dlx6 is
increased in Mecp2-mutant brain.
To assess whether a similar range of variation would be
observed for expression of an imprinted gene, we per-
formed qRT-PCR analyses on the same mouse forebrain
samples, with two different intron-spanning primer sets
for Peg3 (ﬁg. 6B). An increase in Peg3 expression in mu-
tants was seen in some litters but not in others. The sim-
ilarity of patterns obtained with the Peg3A and Peg3B
primer sets suggests that technical variability plays a mi-
nor role. The variation has a biological basis and is un-
related to the Mecp2 genotype. Therefore, we saw no jus-
tiﬁcation for engaging in chromatin modiﬁcation and
chromatin loop assays to evaluate the remaining aspects
of the model described in the previous report. The data
we obtained argue against the foundation of the proposed
model. DLX5 is not imprinted, and there is no relaxation
of imprinting in RTT cell lines or brains and no consistent
overexpression of Dlx5 and Dlx6 in Mecp2-mutant mouse
brain. It is highly unlikely, therefore, that DLX5 is a direct
target of MeCP2.
Discussion
A previous report identiﬁed DLX5 as a target of MeCP2
and drew wide-ranging conclusions linking RTT with ge-
nomic imprinting. The purported “loss of imprinting” of
DLX5 was speculated to have implications for GABA neu-
rotransmission and for autism.24 Numerous articles have
cited the conclusions of Horike et al.24 as facts, with con-
sequences for research on autism, RTT, Angelman syn-
drome, and genomic imprinting.36–43 It is the purpose of
this article to set the record straight. We provide une-
quivocal evidence against the claim that DLX5 is im-
printed in humans and is a direct target of MeCP2 mod-
ulation. As summarized in table 3, we report consistent
biallelic expression in interspecies SCHs, LCLs, and cortex
from normal donors, with no difference between them
and RTT samples. We report the ﬁrst evidence that DLX6
is not imprinted either. This result is expected, since Dlx5
and Dlx6 are coordinately regulated under the control of
Dlx1 and Dlx2 via conserved intergenic enhancers.44 We
also point out the inconsistencies of the previous work,
calling into doubt the claimed subtle preference of ma-
ternal allele expression in normal mouse brain and the
reported twofold increase of expression of Dlx5 and Dlx6
inMecp2-null brain. By comparing forebrain samples from
15 mice from seven litters, we found that expression of
Dlx5 and Dlx6 was highly variable, with no signiﬁcant
differences between male Mecp2-mutants and normal
male littermates. Thus, our serious attempts to replicate
the reported data have yielded absolutely no evidence of
imprinting of DLX5 or evidence of any inﬂuence of
MeCP2 deﬁciency on the expression of DLX5/Dlx5 or
DLX6/Dlx6.
Therefore, any postulated models to explain the non-
reproducible data, such as “silent chromatin loop for-
mation,”24(p38) are unfounded. Attempting to explain their
ﬁnding of increased Dlx5 and Dlx6 expression in Mecp2-
deﬁcient mouse brain, Horike et al.24 identiﬁed a small
region in an intron that contains a single methylatedCpG
500 The American Journal of Human Genetics Volume 81 September 2007 www.ajhg.org
Figure 4. Absence of imprinting of DLX6 in fetal brain. DLX6 genotyping (of gDNA) and expression analysis (of cDNA) in two fetal
brain samples revealed biallelic expression. The 21-wk fetus (left panel) was heterozygous for the known c.*9ArG SNP (rs3213654).
The 17-wk fetus (right panel) was heterozygous for a novel SNP, c.*775dupC. The upper trace displays the reference sequence, GenBank
accession number NM_005222.2. Arrows indicate the positions of nucleotide changes.
site to which MeCP2 binds. Histone-acetylation and
histone-methylation patterns associated with this region
were reported to be different between mutant and wild-
typemouse brains. It was, therefore, claimed that the chro-
matin modiﬁcation differences at this site result in in-
creased Dlx5 expression. On the basis of their prior work
with the nuclear matrix binding protein SATB1 (i.e., spe-
cial AT-rich sequence binding 1) that regulates genes by
folding chromatin into loop domains in thymocytes,45
Horike et al.24 then used a chromosome conformation cap-
ture (3C)method to generate evidence of differential chro-
matin loop formation in wild-type versus Mecp2-mutant
brains. The proposed model of an 11-kb loop of “silent
chromatin” in normal cells and its absence in Mecp2-de-
ﬁcient cells does not, however, correlate with the differ-
ence in allele-speciﬁcDlx5 expression reported in the same
article. If it were true that MeCP2 facilitates a chromatin
loop formation that induces transcriptionally silent chro-
matin, this should lead to reduced expression of Dlx5 and
Dlx6 in normal brain compared with in Mecp2-null brain,
without any allelic difference, because the CpG in the intron
to which MeCP2 presumably binds is equally methylated
on both alleles.24 The model proposed is inconsistent with
the fact that Dlx5 is expressed at high levels in normal
forebrain. If the proposed silencing mechanism were ac-
tive in a brain region, such as the cerebellum, where Dlx5
is not expressed, then MeCP2 deﬁciency should lead to
Dlx5 expression in the mutant cerebellum. But Horike et
al.24 reported only qRT-PCR data for frontal cortex from
8-wk-old Mecp2-mutant mouse. In our cerebellum mi-
croarray studies, Dlx5 expression was not increased in 2-
wk-old, 4-wk-old, and 8-wk-old Mecp2 mutants,17 and the
level of Dlx5 expression in cerebellum was too low to be
reliably measured by use of qRT-PCR. Therefore, the pro-
posed mode of MeCP2 modulation of Dlx5 expression
does not ﬁt the cerebellum expression data either.
That MeCP2 may function in chromatin compaction
was ﬁrst proposed by Georgel et al.,46 an article not cited
by Horike et al.24 By elegant in vitro studies, Georgel et
al. showed that MeCP2 assembles novel secondary chro-
matin structures from nucleosome arrays but does so in-
dependent of DNA methylation. They identiﬁed the C-
terminal domain of MeCP2 as the region necessary for the
nucleosome compaction and suggested that the ability of
MeCP2 to silence chromatin may be related to its effect
on large chromatin organization. Recently, complex in-
teractions of MeCP2 with DNA and chromatin were re-
vealed by the study of mutant constructs, and they could
be divided into methylation-dependent andmethylation-
independent interactions, with multiple chromatin bind-
ing sites identiﬁed.47 The functional implications of these
interactions are yet unknown.
Expression of Human Genes in Rodent # Human SCHs
That Retain a Reduced Number of Human Chromosomes
When the inability to reproduce published data is re-
ported, the discussion needs to focus on experimental de-
sign and methodology. Imprinting of human DLX5 was
ﬁrst reported by Okita el al.,28 who studied expression in
SCHs containing virally tagged single human chromo-
somes. In contrast, we found biallelic expression of DLX5
in two recently generated sets of SCHs that segregate hu-
man chromosomes randomly. Historically, SCHs were a
very useful tool in genetic research. The ﬁrst decade of
human gene mapping relied on the expression of human
genes located on the human chromosomes retained in
interspecies hybrid cell lines. Distinction between the hu-
man and rodent gene products was achieved by electro-
phoretic separation of proteins that either were stained
for activity by substrate binding, in cases of enzymes, or
were immunologically detected with human-speciﬁc an-
tibodies.48 Faithful expression of human genes in the ro-
dent cell environment, regardless of the number or iden-
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Figure 5. Imprinting of PEG3 and PEG10 in MECP2 mutants. A, Maintenance of imprinting of PEG3 in cell lines and brains from males
and females with MECP2 mutations. Samples on the left are heterozygous for the PEG3 c.42CrT SNP (rs1860565) (gDNA); samples on
the right are heterozygous for the c.*703ArG SNP (rs1055359) (gDNA). Arrows indicate the locations of variant nucleotides. As shown
in the right-hand traces (cDNA), all samples express PEG3 from only one allele. B, Maintenance of imprinting of PEG10 in frontal cortex
from one male and two females with MECP2 mutations who are heterozygous for the c.*2923CrT SNP (rs13073). RT-PCR analyses reveal
strictly monoallelic expression (cDNA). Arrows indicate the positions of variant nucleotides.
tity of other human chromosomes present, led to the
assignment of numerous gene loci to chromosomes or
chromosome regions.49 Extensive work by many research-
ers solidiﬁed the notion that the rodent genome contains
all the transcriptional machinery required for expression
of human genes from individual human chromosomes
retained.
The use of rodent # human SCHs to detect allele-spe-
ciﬁc expression of imprinted genes was pioneered by
Meguro et al.50 By use ofmicrocell-mediated chromosome-
transfer methods, the authors generated monochromo-
somal hybrids with mouse A9 cells that retained only a
single virally tagged human chromosome 15 of either pa-
rental origin. Working with these cell lines, Meguro et al.
reported that the three GABAA receptor subunit genes in
the Prader-Willi syndrome/Angelman syndrome deletion
region (GABRB3, GABRA5, and GABRG3) are imprinted
and paternally expressed. This ﬁnding, although still
widely cited, was not conﬁrmed in a later study that used
a large set of preexisting mouse A9# human SCHs.51 Ga-
briel et al.51 validated the general approach, however, by
demonstrating that imprinted expression patterns were
faithfully retained in SCHs containing either maternal or
paternal copies of chromosomes 11 and 15, although the
allele-speciﬁc DNA methylation patterns were rather
variable.
In 1999 and 2001, a Japanese group reported that they
made large sets of monochromosomal hybrids that would
allow the systematic detection of imprinted genes and
other epigenetic phenomena.52,53 A subset of these hybrids
was used to study the imprinted gene cluster on chro-
mosome 7 and led to the report that DLX5 is imprinted,28
a result we could not conﬁrm. The successful use of SCH
lines for the identiﬁcation of imprinted genes relies on
several prerequisites. First, the parental origin of the single
human chromosome retained needs to be reliably iden-
tiﬁed. Second, the transcription unit to be studied has to
be retained intact, because hybrid cells, cultured over ex-
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Table 3. Human DLX5, DLX6, PEG3, and PEG10 Expression
Gene and Sample Expression No. of Samples
DLX5:
SCHs Biallelic 3 mat and 4 pat
RTT LCLs Biallelic 3
Normal LCLs Biallelic 4
Normal fetal brain Biallelic 1
Normal adult cortex Biallelic 5
DLX6:
SCHs Biallelic 3 mat and 4 pat
Fetal brain Biallelic 2
PEG3:
RTT LCLs Monoallelic 3
RTT brain Monoallelic 3
Male MeCP2 -/Y brain Monoallelic 2
PEG10:
RTT brain Monoallelic 2
Male MeCP2 -/Y brain Monoallelic 1
NOTE.—mat p maternal; pat p paternal.
Figure 6. No increase in Dlx5 and Dlx6 expression in Mecp2-mutant mouse brain. A, Expression of Dlx5 and Dlx6 genes in frontal cortex
of Mecp2 mutants (mut) compared with that of wild-type (wt) males from seven different litters, at age 7 wk (litters 1–5) or 9 wk
(litters 6 and 7). For litters with more than one wild type or more than one mutant, individual animals are identiﬁed by different
symbols (designated wt1 and wt2 or mut1 and mut2, respectively). Real-time qRT-PCR data from each mouse were converted to relative
fold changes by comparison with a normalized sample, a wild-type mouse whose level of gene expression was closest to the mean value
for all wild-type data—that is, wt1 in litter 3 for Dlx5 and wt1 in litter 6 for Dlx6. P values calculated by two-tailed, unequal variance
are for Dlx5 and for Dlx6. P values calculated by one-tailed, unequal variance are for Dlx5 andPp .4984 Pp .5134 Pp .2492 Pp
for Dlx6. The plots illustrate the wide variability within and between litters. B, Expression of the imprinted gene Peg3, studied.2567
in the same forebrain samples used in ﬁg. 6A, by qRT-PCR with two different primer sets (Peg3A and Peg3B). Expression levels were
normalized to the same housekeeping gene, Rps28. The wide range of expression levels in individual mice and the similarity of patterns
obtained with Peg3A and Peg3B primer sets indicate biological noise rather than technical variation.
tended periods, may undergo chromosome losses, rear-
rangements, and mutations. Third, the method for detec-
tion of expression must reliably distinguish the human
and the rodent gene products. In the studies reportedhere,
we used well-characterized hybrid cells that were derived
from two unrelated human donors for whom the parental
origin of chromosome 7 alleles had been unequivocally
established by genotyping all four parents. The SCH lines
had been in culture for only a limited time. Originally, we
chose two SCHs from each donor that had retained the
paternal chromosome 7 and two that had retained the
maternal copy, but one of the four lines with thematernal
chromosome 7 subsequently lost this chromosome, as de-
termined by PCR ampliﬁcation of gDNA. Our DLX5 prim-
ers were speciﬁc to cDNA, not ampliﬁcation of gDNA. Our
primers also were designed with sufﬁcient mismatches
against themouse sequence, to ensure that nomouse tran-
script would be ampliﬁed, and we used mouse brain RNA
as a negative control. We detected unambiguous ampli-
ﬁcation of only human-speciﬁc transcripts of DLX5 and
DLX6 in SCH lines containing either the maternal (three
lines) or the paternal (four lines) chromosome 7, contra-
dicting the ﬁndings of Okita et al.28 We note that other
data in their article are doubtful as well. Although the
authors show imprinted paternal-speciﬁc expression for
PEG10, conﬁrming previous studies in humans and mice,
they report biallelic expression for SGCE. This gene is well
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known to be imprinted and paternally expressed in hu-
man and mouse.54–57 Okita et al. further claimed paternal-
only expression for paraoxonase 1 (PON1), a gene that
was not conﬁrmed to be imprinted in a subsequent
study.58
Use of LCLs for Imprinting Studies
LCLs are derived from peripheral blood B cells by trans-
formation with Epstein-Barr virus.59 They are immortal,
although variable in growth rates. Given their transformed
nature, LCLs may express tissue-speciﬁc genes that are not
normally expressed in untransformed B cells. Therefore,
the study of neurodevelopmental genes, like DLX5 and
DLX6, that are expressed ectopically and at a very low
level in LCLs, could lead to failure to amplify RT-PCRprod-
ucts from both alleles (as reported by Okita et al.28 and
Horike et al.24). Horike et al. reported monoallelic expres-
sion of DLX5 in two normal LCLs and biallelic expression
in three of four RTT LCLs. In our experience, only after
multiple optimization steps were we able to document
consistent biallelic expression of this ectopically expressed
locus in all normal control and RTT LCLs. This point is
very well illustrated in a recent article by Itaba-Matsumoto
et al.,39 which reported studies of 12 LCLs from individuals
with RTT and identiﬁed MECP2 mutations who were het-
erozygous for DLX5 c.*163dupC/rs5886002. The authors
estimated the degree of X-inactivation mosaicism in these
LCLs by deducing relative mutant/wild-type MECP2 ex-
pression levels from cDNA sequence tracings. Six LCLs
were completely skewed and expressed only wild-type
MECP2. Three of those showed biallelic DLX5 expression.
Moreover, of ﬁve LCLs with 25%–75% mutant MECP2 ex-
pression, two showed biallelic DLX5 expression, as did
some LCLs from unaffected individuals. Itaba-Matsumoto
et al. concluded that they could not reproduce the data
reported by Horike et al., but only with regard to MECP2
mutation-type–speciﬁc loss of imprinting of DLX5. Itaba-
Matsumoto et al.39 did not question the imprinting status
of this gene in normal cells and wrote in their abstract,
“a sample with high expression of mutatedMECP2 in TRD
mutation showed bialleic [sic] expression of DLX5 sug-
gesting loss of imprinting.”39 Since these authors were able
to amplify only one DLX5 allele in 50% of their cell lines,
with no relationship to mutant MECP2 expression levels, their
data suggest technical difﬁculties with RT-PCR caused by
low DLX5 expression levels in LCLs.
Although lymphoblast DNA may acquire differential
methylation patterns after establishment in culture,60
LCLs have been used successfully for global gene-expres-
sion analyses.61 Previous studies reported that monoallelic
expression patterns of imprinted genes on chromosomes
11 and 15 are maintained in LCLs.51 Moreover, monoal-
lelic expression was reported for imprinted genes in LCLs
from individuals with RTT.20 To further validate the use
of LCLs for imprinting studies, we analyzed the expression
of PEG3, an imprinted locus on chromosome 19. We
found PEG3 to be strictly monoallelically expressed in RTT
LCLs that were completely skewed for X inactivation, ex-
pressing either 100% mutant or 100% wild-type MeCP2.
Partial Imprinting or Allelic Imbalance
In studies of the forebrain, in which DLX5 is highly ex-
pressed, low cDNA copy number should not be an issue
for transcript ampliﬁcation. Indeed, biallelic expression
was found in two of three human brain samples studied
by Okita et al.28 However, on the basis of inspection of
band intensities on sequencing gels, the authors con-
cluded that expression is unequal, with preferential ex-
pression of a single allele of unknown parental origin. Our
studies revealed unambiguous expression of both DLX5
alleles in six cortex samples from heterozygous individ-
uals, ranging in age from 18 fetal wk to 70 years. Likewise,
DLX6 was biallelically expressed in two fetal brains that
were heterozygous for a known and a novel SNP, respec-
tively. Therefore, DLX5 and DLX6 are not imprinted in
human brain, andwe have not observed apparent unequal
expression.
Consistent with our results in human,Dlx5was reported
to be biallelically expressed inmultiple brain regions, with
no allele-speciﬁc preference, in F1 mice of interspecies
crosses.26 By using the same approach, Horike et al., how-
ever, reported “preferential expression from the maternal
allele”24(p33) in control mouse brains. This pattern was said
to be changed to “equal expression” of Dlx5 alleles in a
single Mecp2-mutant brain. This result led the authors to
conclude that “MeCP2 deﬁciency leads to complete loss
of relaxed imprinting in brain.”24(p33) The evidence consists
of restriction-enzyme digestion of RT-PCR products from
heterozygous templates. In this system, quantitation of
alleles is difﬁcult because, at the end of the PCR cycles,
when the sample is cooling down, denaturation and re-
naturation may occur, leading to the formation of het-
eroduplexmolecules that are not susceptible to restriction-
enzyme cleavage. This phenomenon results in the larger
uncleaved band appearing relatively stronger. In addition,
the cleaved allele is represented by two smaller bands
whose combined ﬂuorescent intensity should approxi-
mate that of the uncleaved allele. The pattern expected
from a template with both alleles equally represented is
illustrated by the gDNA results for the four imprinted
genes in ﬁgure 2b in the work of Horike et al.,24 in which
the largest fragment is always the most intense one. In
ﬁgure 2a, a single Mecp2-mutant RNA sample is shown
with exactly the same intensity of two bands, representing
the 636-bp uncut and 533-bp cut Dlx5 allelic fragments.
The smaller 103-bp restriction fragment, representing part
of the cleavable allele, is cut off. This result would not be
expected if both alleles were expressed equally. Therefore,
the data do not support the claim of parent-of-origin–
speciﬁc allelic imbalance of Dlx5 expression in normal
brain and a role for MeCP2 in maintaining a maternal
preference indicating relaxed imprinting.
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Allelic variation in gene expression for nonimprinted
genes is increasingly being recognized. The magnitude
varies from a 1.3-fold to 9-fold difference in 20%–50% of
the genes tested.62–66 Interestingly, allelic transcript vari-
ants may follow Mendelian inheritance because of vari-
ation in cis-acting elements or “regulatory SNPs.”67 There-
fore, unequal allelic expression levels of any gene should
not be casually interpreted as “partial imprinting.” Con-
fusion could arise for genes that are imprinted in a cell
type–speciﬁc fashion, if the sample tested were a mixture
of cells affected by the imprinting and cells that are not.
There is no evidence that the genes discussed here fall
into this category.
Horike et al.24 provided circumstantial evidence in sup-
port of the fact that Dlx5 is not imprinted in mouse brain,
by showing that there are no DMRs in the vicinity ofDlx5/
Dlx6 and that the promoters of both genes are unmethy-
lated on both alleles. Evolutionary considerations lend ad-
ditional support. As epigenetic phenomena evolve in
mammalian species, there are well-established epigenetic
differences between humans and mice. In humans, ∼15%
of X-linked genes are biallelically expressed—that is, es-
cape from X inactivation—which is not the case inmice.68
Likewise, the list of known imprinted genes contains
many that are imprinted inmice but biallelicallyexpressed
in humans.19
No Role for MeCP2 in Imprinting
To determine whether truly imprinted genes maintain
their imprinting status in MeCP2-deﬁcient brain, we stud-
ied PEG3 and PEG10 expression in cortex samples from
mosaic females with RTT, as well as from nonmosaicmales
with congenital encephalopathy who are hemizygous for
MECP2 mutations. The strictly monoallelic expression of
PEG3 and PEG10 conﬁrms that the lack of normal MeCP2
protein does not abolish or relax the imprinting status of
imprinted loci (table 3). Ten imprinted transcripts have
previously been shown tomaintain their imprinting status
in MeCP2-deﬁcient tissues from humans and/or mice:
H19, IGF2, SNRPN, IPW, and NDN,20 as well as KCNQ1OT1
(or LIT1), Sgce, Peg10, Asb4, and Calcr.24 Although the role
of DMRs for the maintenance of imprinting is undisputed,
MeCP2 is unlikely to be the CpG binding molecule that
translates this methylation signal.
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